Jaromír Zahrádka is Chief Executive Officer and co-founder of i&i Prague, a biotech incubator and investment company owned by The Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech Republic, v.v.i. (IOCB) in Prague, Czech Republic. IOCB Prague, a public research institute, is well known due to antivirotics and peptide drugs. Among others, the HIV therapy blockbuster Tenofovir TM, marketed by Gilead, originated at IOCB Prague.
i&i Prague is accelerating the proof-of-concept stage of projects in the fields of Medtech, Diagnostics and Drug discovery. The company focuses on scalable projects with excellent innovative potential in discovery, pre-seed or seed phase. Since the company is an investment company, it is able to support projects with pre-seed and seed investment and invite further co-investors to participate.
In total, more than 15 projects are in broader portfolio of i&i Prague including projects from Czech Republic, Germany, Austria or Slovakia and Jaromir already participated in establishment of 5 spin-off companies including Riocath Medical Devices, DIANA Biotechnologies or Elfogene companies and he was involve in more than 10 significant out-licensing deals in the biotech field.
Jaromir hold MSc. and Ph.D. in Biochemistry from the Charles University in Prague and he earned another master degree in Corporate Economics, Management and Enterprise valuation at The University of Economics in Prague. Using his economical background in combination with his scientific expertise, he will provide complex perspective for evaluation of the project´s potential and feasibility. Furthermore, he has developed an expertise in early-phase technologies valuation and market potential analysis for biotech RnD projects and he is lecturing at several universities.